Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Lanadelumab-flyo is a prescription plasma kallikrein inhibitor marketed as Takhzyro. It is indicated for prophylaxis to prevent hereditary angioedema attacks in adults and children age 2 and older. It is administered by subcutaneous injection.
read more about lanadelumab ...Lanadelumab-flyo is a monoclonal antibody that binds plasma kallikrein and inhibits its proteolytic activity. This reduces generation of bradykinin, a mediator that increases vascular permeability and contributes to swelling and pain during hereditary angioedema attacks.
Lanadelumab is used for routine prevention of hereditary angioedema attacks in patients age 2 and older. It is not an acute rescue treatment for an attack that has already started.
Patients age 12 and older receive 300 mg subcutaneously every two weeks, with every-four-week dosing considered after more than six months of good control. Children age 6 to younger than 12 receive 150 mg every two weeks, with every-four-week dosing considered after sustained control. Children age 2 to younger than 6 receive 150 mg every four weeks.
Hypersensitivity reactions, including serious reactions, can occur and require discontinuation and treatment when severe. Injection-site reactions are the most common adverse reactions. Other commonly reported reactions include upper respiratory infections, headache, rash, dizziness, diarrhea, and muscle pain.
Lanadelumab is used to prevent hereditary angioedema attacks in patients age 2 and older.
The recommended starting dose is 300 mg subcutaneously every two weeks.
The recommended dose is 150 mg subcutaneously every four weeks.
No. It is a preventive treatment rather than an acute rescue medicine.
DailyMed - TAKHZYRO (lanadelumab-flyo) injection, solution. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?lang=en&setid=15f99d8c-efe7-4f7d-aa20-0d0f1e30c6e8. Date Accessed October 8, 2026.
Lanadelumab-flyo Injection. MedlinePlus. https://medlineplus.gov/druginfo/meds/a622035.html. Date Accessed October 8, 2026.
Purple Book Search - Takhzyro. U.S. Food and Drug Administration. https://purplebooksearch.fda.gov/index.cfm?blaNo=761090&event=productdetails. Date Accessed October 8, 2026.
Search Orphan Drug Designations and Approvals - Takhzyro. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=397213. Date Accessed October 8, 2026.
TAKHZYRO (lanadelumab-flyo) Prescribing Information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761090s010lbl.pdf. Date Accessed October 8, 2026.